BNET Industries

Market Cap:$147.2B
Last Fiscal Year Sales:$48.4B
- Public
- US
Dow Jones Description
Taking care of you and your four-legged friends too! Pfizer Inc. (NYSE: PFE), based in New York, NY, discovers, develops, manufactures and sells prescription medications for humans and animals. Employing about 115,000 people, this $51.3 billion company operates in three segments: Human Health, Consumer Healthcare and Animal Health. Together, these segments cover treatments for diseases such as cardiovascular and metabolic diseases, medications for oral care, tobacco dependence, and products for prevention and treatment of diseases in livestock and pets.
Number of Employees 81,800
Peer Companies
NAICS Code Pharmaceutical Preparation Manufacturing: 325412
Recent Events
-
Roche's Merger Formula for Genentech
-
Pfizer PFE Will Not Renew Ethical Distribution Agreement Term with MWI Veterinary Supply MWIV
-
Pfizer Inc. and Wyeth; Analysis of Agreement Containing Consent Order To Aid Public Comment and...
-
A 2nd Loss for Pfizer in Drug Suits
-
Pfizer acquires stem cell therapies assets of Axordia
-
Standpoint Raised Its FY10 Price Target on Pfizer PFE to $24
-
ImmunoVaccine signs exclusive licence deal with Pfizer
-
Pfizer Animal Health selects Bader Rutter as agency of record
-
FDA panel backs Pfizer's anti-infection vaccine for kids
-
Cash Just Kept On Piling Up, But It Looks Like The Spending Has Started
-
Goldman Sachs Said Pfizer PFE Best Positioned US Pharma in China
-
EDITORIAL: Difficult mix of business, science
-
$75M verdict unsealed in Prempro-cancer case
-
Sanofi-Aventis on hunt for Boston partners
-
Pfizer says in partnership deal with BMP in China
-
Pfizer Inc. PFE Says in Partnership Deal with BMP Sunstone in China
-
Still Enjoying Those Acquisitions, Pfizer?
-
Status Of Pfizer And Wyeth Research Facilities
-
Monsanto MON Agrees to Acquire Pfizer's PFE Chesterfield Village Research Center for $435M
News & Analysis
Filter by
pfizer inc. and sanofi-aventis - All News and Analysis
Yangtze River Delta Developing Huge R&D Base for Drug Companies
ChinaBio Today submits: [Editor’s note: The following article originates from coverage of the BioBay Investor Forum 2008, presented by ChinaBio on August 27/28 in Suzhou. It was hosted by BioBay, the life science park in Suzhou. The article is reprinted with permission from Interfax China. Interfax China pharma news...
Big Pharma Pipeline: Why So Dry?
Saj Karsan submits: Pharmaceutical companies are trading well below their historical P/E levels. To anyone who follows the industry, this comes as no surprise. After a slew of blockbuster drugs that hit the market several years ago, the R&D departments of the largest companies have been coming up empty as...
Tough Projections for Big Pharmas: Drug Revenues Don't Look Promising
Derek Lowe submits: Well, today’s subject isn’t a cheerful data set, but it certainly deserves some thought. Over at Pharmalot, Ed Silverman has some data from consulting firm AVOS Life Sciences, which has sat down to estimate how well various drug companies will do with revenue from new drugs...
Time to Invest in Pharmaceuticals?
Howard Sun submits: The prices of many pharmaceutical companies have been beaten down by Wall Street in recent months. With companies like Pfizer PFE, Schering-Plough SGP and Bristol-Myers Squibb BMY reaching lower lows, one has to wonder when the pain will end as these companies are now significantly undervalued. The...
Zacks Analyst Interview Highlights: Pfizer, Bristol Myers Squibb, Sanofi-Aventis and Merck
CHICAGO -- Zacks.com releases the latest Analyst Interview. Today's interview is with senior analyst Jason Napodano, who discusses Pfizer (NYSE: PFE), Bristol Myers Squibb (NYSE: BMY), Sanofi-Aventis (NYSE: SNY) and Merck (NYSE: MRK).
Zacks Analyst Interview Highlights: Pfizer, Eli Lilly, Bristol-Myers Squibb and Sanofi-Aventis
CHICAGO -- Zacks.com releases the latest Analyst Interview. Today's interview is with senior analyst Jason Napodano, who discusses Pfizer (NYSE: PFE), Eli Lilly (NYSE: LLY), Bristol-Myers Squibb (NYSE: BMY) and Sanofi-Aventis (NYSE: SNY).
Zacks Analyst Interview Highlights: Pfizer, Abbott Labs, AstraZeneca, Sanofi-Aventis and GlaxoSmithKline
CHICAGO -- Zacks.com releases the latest Analyst Interview. Today's interview is with senior analyst Jason Napodano, who discusses Pfizer (NYSE: PFE), Abbott Labs (NYSE: ABT), AstraZeneca (NYSE: AZN), Sanofi-Aventis (NYSE: SNY) and GlaxoSmithKline (NYSE: GSK).
Pfizer, Novartis and Sanofi-Aventis captivate pharmaceutical business researchers' interests; Analysis of Piribo.com shows areas of pharmaceutical industry preoccupation.
LONDON, UNITED KINGDOM, Jul 9, 2007 CCNMatthews via COMTEX -- Pfizer, Novartis and Sanofi-Aventis were the three most searched for companies in the first five months of 2007 on the pharmaceutical business intelligence website Piribo.com. LONDON, UNITED KINGDOM, Jul 9, 2007 CCNMatthews via COMTEX...
Zacks Analyst Blog Highlights: Neurocrine Biosciences, Sanofi-Aventis, Sepracor, Pfizer and Vivo Participacoes S.A
CHICAGO -- Zacks.com announces the list of stocks featured in the Analyst Blog. Every day, the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Neurocrine Biosciences (Nasdaq:NBIX), Sanofi-Aventis (NYSE:SNY), Sepracor (Nasdaq:SEPR), Pfizer (NYSE:PFE) and Vivo...
New Research Examines How Successful the Pipeline Enhancement Process has been in Practice for four 'Mega Corporations' - AstraZeneca, GlaxoSmithKline, Pfizer, and Sanofi-Aventis
DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c32166) has announced the addition of Mega Corporation Pipelines: A Postmerger Analysis to their offering.
- 1
- 2
Industry Transcripts by Seeking Alpha
-
Avanir Pharmaceuticals F4Q09 (Qtr End 09/30/2009) Earnings Call Transcript
on Nov 24, 2009about AVNR
-
Palatin Technologies F1Q10 (Qtr End 9/30/09) Earnings Call Transcript
on Nov 16, 2009about PTN
-
Flamel Technologies SA Q3 2009 Earnings Call Transcript
on Nov 16, 2009about FLML
-
NexMed Inc. Q3 2009 Earnings Call Transcript
on Nov 10, 2009about NEXM
-
InterMune, Inc. Q3 2009 Earnings Call Transcript
on Nov 10, 2009about ITMN
IndustryTop Rated
- How NOT to Write a Biotech Press Release: Just Ask Epeius 5 votes
- Biogen Idec's Social Media Ties Save Tysabri Again; FDA Watching 3 votes
- Teva, In Turnabout, Sues to Protect Its Multiple Sclerosis Drug Copaxone 3 votes
- BioCryst's Antiviral Drug Peramivir Aims to Keep Swine-Flu Body Count Low 3 votes
- More Tysabri Problems; Time for a Biogen-Idec Credibility Check 3 votes

